UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Clinical trials for UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a common heart drug boost cancer treatment?
Disease control Recruiting nowThis study tests whether adding propranolol (a beta-blocker used for heart conditions) to standard chemotherapy and immunotherapy can help people with advanced esophageal or stomach cancer that cannot be surgically removed. The drug may reduce stress hormones that can weaken the …
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated May 17, 2026 02:01 UTC
-
New combo shows promise for tough stomach cancers
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) helps people with advanced stomach or esophageal cancer live longer without their disease getting worse. About 224 adults whose cancer has a specific marker (PD-…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New immune cocktail targets tough stomach cancers
Disease control Recruiting nowThis study tests a mix of immune cells (agenT-797) and three immunotherapy drugs (botensilimab, balstilimab, ramucirumab) plus chemotherapy (paclitaxel) for people with advanced stomach, esophageal, or gastro-esophageal junction cancer that has worsened after one prior treatment.…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New chemo cocktail aims to extend life in hard-to-treat stomach cancers
Disease control Recruiting nowThis study compares two chemotherapy combinations for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. About 382 participants will receive either the standard FOLFOX chemo (with or without the immunotherapy nivolumab…
Matched conditions: UNRESECTABLE ESOPHAGEAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 04, 2026 16:18 UTC